Reneuron Group (RENE)


Latest News

Notification of Interim Results

RNS Number: 3245W ReNeuron Group plc 13 November 2017 13 November 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Notification of Interim Results ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics , intends to announce its interim results for the six months ended 30 Septembe...

ReNeuron clinical trial enters next phase

ReNeuron Group said its retinal disease clinical trial had moved into its second phase following approval from a data safet...

Retinal disease clinical trial moves into Phase II

RNS Number: 8587V ReNeuron Group plc 08 November 2017 8 November 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Retinal disease clinical trial moves into Phase II Data Safety Monitoring Board gives approval for ongoing retinitis pigmentosa clinical trial to progress into Phase II element based on short term safety data ReNeuron Gr...

ReNeuron reports positive trial data

ReNeuron Group has provided an update on the Phase II clinical trial of its CTX cell therapy candidate for stroke disabilit...

All News

13-11-17Notification of Interim ResultsRNS
08-11-17ReNeuron clinical trial enters next phaseStockMarketWire
08-11-17Retinal disease clinical trial moves into Phase IIRNS
31-10-17ReNeuron reports positive trial dataStockMarketWire
31-10-17Positive stroke clinical data & regulatory updateRNS
27-10-17ReNeuron wins Welsh grantStockMarketWire
27-10-17Wins further UK grantRNS
11-10-17PDMR Interest in Shares and Share OptionsRNS
09-10-17Presentation of positive pre-clinical dataRNS
12-09-17Directors' Interest in Shares and Share OptionsRNS
06-09-17Result of AGMRNS
06-09-17AGM Trading UpdateRNS
01-09-17Non-executive Director AppointmentRNS
01-09-17Block Listing Review and TVRRNS
07-08-17Neil Woodford 'very confident' he can deliver 10%-plus yearly returnsMoney Observer
07-08-17Posting of Annual Report and Notice of AGMRNS
04-08-17Second Price Monitoring ExtnRNS
04-08-17Price Monitoring ExtensionRNS
25-07-17Appointment of joint brokerRNS
19-07-17Board changeRNS
29-06-17ReNeuron widens FY pretax lossStockMarketWire
29-06-17Preliminary ResultsRNS
19-06-17ReNeuron says FDA okays cryopreserved hRPC formulationStockMarketWire
19-06-17FDA approves cryopreserved hRPC formulationRNS
08-06-17Notification of Preliminary ResultsRNS
05-06-17ReNeuron gets favourable feedback from US FDAStockMarketWire
05-06-17Positive FDA feedback on proposed Phase III studyRNS
18-05-17ReNeuron presents positive exosome dataStockMarketWire
18-05-17Presents positive exosome data at major conferenceRNS
11-05-17ReNeuron awarded £1.8m grant from Innovate UKStockMarketWire
11-05-17Awarded major UK cell therapy manufacturing grantRNS
05-05-17Presents new exosome data at major conferenceRNS
21-04-17ReNeuron updates on ophthalmology programmesStockMarketWire
21-04-17ReNeuron updates on clinical strategy in stroke disabilityStockMarketWire
21-04-17Update on clinical strategy in stroke disabilityRNS
21-04-17Update on progress in ophthalmology programmesRNS
01-03-17Block Listing Review and Total Voting RightsRNS
15-02-17ReNeuron featured in BBC documentaryRNS
07-02-17Director Deals - ReNeuron Group PLC (RENE)StockMarketWire
07-02-17Director Share PurchaseRNS

RSS feeds

  • Editorial news feed for LSE:RENE Editorial
  • Regulatory news feed for LSE:RENE Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account